Top High Tech Companies To Buy For 2015

LONDON — Fears of a long slide in the FTSE 100 (FTSEINDICES: ^FTSE  ) seem to have been put on hold for the time being, with the U.K.’s top-tier index putting in a couple of days of gains — it’s up 0.93% to 6,389 points by 9:15 a.m. EDT. That puts it 953 points up on its 52-week low of 5,436, and few will be expecting it to get anywhere near those lows anytime soon.

But if we want to see some companies that are trading around their 52-week lows, we need look no further than those involved in natural resources. Here are three from the various indexes.

Rockhopper (LSE: RKH  )
Rockhopper Exploration shares have been on a long slide since last summer, having lost more than 59% of their value over the past 12 months. And today, at 127 pence, they’re bumping around their two-year low of 125 pence.

The firm operates in the waters around the Falklands, and hopes for the region were high just a couple of years ago — but a number of dry wells in the area have dented confidence. But Rockhopper has had some exploratory success, so does it still have a chance of turning a profit? That’s for you to decide.

Top High Tech Companies To Buy For 2015: Beacon Roofing Supply Inc.(BECN)

Beacon Roofing Supply, Inc. distributes residential and non-residential roofing materials. The company?s residential roofing products include asphalt shingles, synthetic slates and tiles, clay and concrete tiles, slates, nail base insulation, metal roofing, felt, wood shingles and shakes, nails and fasteners, metal edgings and flashings, prefabricated flashings, ridges and soffit vents, gutters and downspouts, and other accessories. Its non-residential roofing products comprise single-ply roofing; asphalt; metal; modified bitumen; built-up roofing; cements and coatings; insulation?flat stock and tapered; commercial fasteners; metal edges and flashings; skylights, smoke vents, and roof hatches; and sheet metal products, including copper, aluminum, and steel. The company also provides complementary building products, such as vinyl siding; red, white, and yellow cedar siding; fiber cement siding; soffits; house wraps; vapor barriers; and stone veneer, as well as vinyl windo w s, aluminum windows, wood windows, turn-key windows, and wood and patio doors. In addition, it offers specialty lumber products comprising redwood, red cedar decking, mahogany decking, pressure treated lumber, fire treated plywood, synthetic decking, PVC trim boards, millwork, and custom millwork. Further, the company provides waterproofing systems, building insulations, air barrier systems, gypsum, moldings, cultured stone, and patio covers. Its customer base consists of contractors, home builders, building owners, and other resellers. Beacon Roofing Supply, Inc. distributes its products through 194 branches in 38 states of the United States; and 6 Canadian provinces. The company was founded in 1928 and is based in Peabody, Massachusetts.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Beacon Roofing Supply Inc.’s(BECN) fiscal fourth-quarter earnings declined slightly as higher costs offset a jump in sales. “We continued to experience a challenging pricing environment, which drove down our gross margins from the prior year,” Chief Executive Paul Isabelle said. Results missed estimates, sending shares down 4.4% to $34.50 in light premarket trading.

  • [By Lee Samaha]

    It’s been a volatile year for the roofing industry, and over the last three months, investors have seen more downside. Roofing materials distributor Beacon Roofing Supply (NASDAQ: BECN  ) is down 11.5% in the last three months, and building products manufacturer Owens Corning (NYSE: OC  ) fell 5.5% in the same period — all in a year when many commentators thought this sector would outperform. 

Top High Tech Companies To Buy For 2015: Synta Pharmaceuticals Corp.(SNTA)

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drug candidates for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its oncology product portfolio includes Ganetespib, an Hsp90 inhibitor in various phase 1, 2, and 3 clinical trail programs for various types of cancers, including non-small cell lung cancer, gastrointestinal stromal tumors, hematologic cancers, colorectal cancer, gastric cancer, small cell lung cancer, ocular melanoma, pancreatic cancer, prostate cancer, breast cancer, hepatocellular cancer, and solid tumors; Elesclomol, a mitochondria-targeting agent in phase 2 clinical trails for non-small cell lung cancer and ovarian cancer, as well as in phase 1 clinical trail for acut e myeloid leukemia; STA-9584, a vascular disrupting agent in preclinical development stage for prostate cancer; and various Hsp90 inhibitors in preclinical development stage for cancers. The company?s inflammatory diseases product portfolio includes calcium release activated calcium modulator (CRACM) channel inhibitors in preclinical development stage for autoimmune diseases, respiratory conditions, and transplantation; and IL-12/23 inhibitors in lead optimization stage for autoimmune diseases. It has a license agreement with Hoffman-La Roche for the development and commercialization of compounds from CRACM. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

Advisors’ Opinion:

  • [By James E. Brumley]

    Looks out Synta Pharmaceuticals Corp. (NASDAQ:SNTA), and AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), you’re on notice too. Corcept Therapeutics Incorporated (NASDAQ:CORT) is nipping at your heels, and better still, shares of the company looks like they’re about to dole out a sizeable reward to investors who see the writing on the wall.

  • [By Lauren Pollock]

    Synta Pharmaceuticals Corp.(SNTA) said it intends to offer an unspecified number of shares to the public. The biopharmaceutical company has about 69 million shares outstanding. Shares dropped.

  • [By Sean Williams]

    What: Shares of Synta Pharmaceuticals (NASDAQ: SNTA  ) , a clinical-stage biopharmaceutical company focused on researching and developing cancer and chronic inflammatory therapies, fell as much as 17% following an analyst downgrade after Synta disclosed the departure of its president of research & development.

Top High Tech Companies To Buy For 2015: Green Automotive Co (GACR)

Green Automotive Company, incorporated on November 15, 1996, is a vehicle design, engineering, manufacturing and distribution company. The Company also provides after sales program. It possesses a portfolio of businesses and is active in three main market segments: Cutting edge technology development, engineering and design with a focus on zero and low emission vehicle solutions; Manufacturing and customization of vehicles for markets with the potential to be converted into low emission or electric vehicles, such as shuttle buses, taxis, commercial vehicles, and After sales services for electric or low emission vehicles, including servicing and repair. On December 14, 2012, the Company closed its merger with Matter of Time I Co. As per the merger agreement, Matter of Time I Co. dissolved into and became a part of Green Automotive Company, with Green Automotive Company being the surviving corporation. In January 2014, Green Automotive Co Inc acquired a 21.63% interest in Vi ridian Motor Corp Inc.

The Company’s two divisions servicing the three segments are Liberty Electric Cars Ltd and Newport Coachworks Inc. Liberty Electric Cars Ltd designs and develops EV technologies for use in its own converted vehicles and for sale to original equipment manufacturers (OEM’s) for incorporation into its production. In addition, it provides an aftermarket program for electric vehicle users to ensure the longevity of their vehicles. Newport Coachworks Inc. specializes in building shuttle buses, running on a variety of energy sources from petrol and diesel though to compressed natural gas (CNG).

The Company competes with Zytec, AMPD, Siemens, Tiffany, Krystal, Ford, and General Motors, Cummins and Freightliner.

Advisors’ Opinion:

  • [By John Udovich]

    A security consultant warns that $100,000 electric cars from Tesla Motors Inc (NASDAQ: TSLA) could be unlocked by criminals plus a quick wrap up of other interesting electric vehicle or stock news from small cap EV stocks like Kandi Technologies Group Inc (NASDAQ: KNDI) and Green Automotive Company (OTCMKTS: GACR):

  • [By Bryan Murphy]

    On Tuesday of this week, yours truly pointed out that based on 2013’s final numbers, Green Automotive Co. (OTCMKTS:GACR) – while not yet a threat to names like Kandi Technologies Group Inc. (NASDAQ:KNDI) or Tesla Motors Inc. (NASDAQ:TSLA) – was coming into its own as an electric vehicle company, and whittling away its uncertainty as an investment. Though a perfectly-clear vision of the future wasn’t included in the press release detailing last year’s results for GACR, the company did say it would be offering guidance for 2014 later this week. Well, today’s the day. And, while KNDI and TSLA still don’t have anything to worry about in their immediate future, let’s just say Green Automotive still have a lot to look forward to in their foreseeable future.

Top High Tech Companies To Buy For 2015: LHC Group Inc (LHCG)

LHC Group, Inc. (LHC Group), incorporated on January 1, 2005, provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals (LTACHs). As of December 31, 2012, through the Company’s wholly- and majority-owned subsidiaries, equity joint ventures and controlled affiliates, the Company operated in Alabama, Arkansas, Florida, Georgia, Idaho, Kentucky, Louisiana, Maryland, Mississippi, Missouri, North Carolina, Ohio, Oklahoma, Oregon, Tennessee, Texas, Virginia, West Virginia and Washington. The Company operates in two segments: home-based services and facility-based services. As of December 31, 2012, the Company owned and operated 274 home-based service locations, with 232 home nursing agency locations, 32 hospices, three specialty agencies and four private duty agencies. In February 2014, LHC Group Inc acquired two home health providers.

As of December 31, 2012, the Company also managed the oper ations of three home nursing agencies in which the Company does not have an ownership interest. The Company’s facility-based services included six long-term acute care hospitals with nine locations, a pharmacy, and a family health center. The Company provides home-based post-acute health care services through its home nursing agencies and hospices. The Company’s home nursing locations offer a wide range of services, including skilled nursing, medically-oriented social services and physical, occupational and speech therapy. The nurses, home health aides and therapists in the Company’s home nursing agencies work closely with patients and their families to design and implement individualized treatments in accordance with a physician-prescribed plan of care.

The Company’s hospices provide end-of-life care to patients with terminal illnesses through interdisciplinary teams of physicians, nurses, home health aides, counselors and volunteers. Of the 274 home-based ser vices locations, 140 are wholly-owned by the Company, 124 ar! e majority-owned or controlled by the Company through joint ventures, seven are operated through license lease arrangements, and the Company manages the operations of three home nursing agencies in which the Company has no ownership interest.

The Company’s LTACH locations provide services primarily to patients with complex medical conditions who have transitioned out of a hospital intensive care unit but whose conditions remain too severe for treatment in a non-acute setting. As of December 31, 2012, the Company’s LTACHs had 220 licensed beds. Of the Company’s 11 facility-based services locations, six are wholly-owned by the Company and five are majority-owned or controlled by the Company through joint ventures.

Home-Based Services

The Company’s registered and licensed practical nurses provide a range of medically necessary services to homebound patients who are suffering from acute or chronic illness, recovering from injury or surgery, or w ho otherwise require care, teaching or monitoring. These services include wound care and dressing changes; cardiac rehabilitation; infusion therapy; pain management; pharmaceutical administration; skilled observation and assessment, and patient education. It has also designed guidelines to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer’s disease, low vision, spinal stenosis, Parkinson’s disease, osteoporosis, complex wound care and chronic pain. Its home health aides provide assistance with daily living activities, such as light housekeeping, simple meal preparation, medication management, bathing and walking. Through its medical social workers, it counsels patients and their families with regard to financial, personal and social concerns that arise from a patient’s health-related problems.

The Company provides skilled nursing, ventilator and tracheotomy services, extended care specialties, medication adminis tration and management, and patient and family assistance an! d educati! on. It also provides management services to third-party home nursing agencies, often as an interim solution until proper state and regulatory approvals for an acquisition can be obtained. The Company’s physical, occupational and speech therapists provide therapy services to patients in their home. Its therapists coordinate multi-disciplinary treatment plans with physicians, nurses and social workers to restore basic mobility skills, such as getting out of bed and walking safely with crutches or a walker Its therapists assist patients and their families with improving and maintaining a patient’s ability to perform functional activities of daily living, such as the ability to dress, cook, clean and manage other activities safely in the home environment. Its speech and language therapists provide corrective and rehabilitative treatment to patients who suffer from physical or cognitive deficits or disorders that create difficulty with verbal communication or swallowing.

All of the Company’s home nursing agencies offer 24-hour personal emergency response and support services through Philips Lifeline (Lifeline) for qualified patients who require close medical monitoring but who want to maintain an independent lifestyle. These services consist principally of a communicator that connects to the telephone line in the subscriber’s home and a personal help button that is worn or carried by the individual subscriber which, when activated, initiates a telephone call from the subscriber’s communicator to Lifeline’s central monitoring facilities. Lifeline’s trained personnel identify the nature and extent of the subscriber’s particular need and notify the subscriber’s family members, neighbors and/or emergency personnel, as needed.

The Company’s Medicare-certified hospice operations provide a range of hospice services designed to meet the individual physical, spiritual and psychosocial needs of terminally ill pa tients and their families. Its hospice services are primaril! y provide! d in a patient’s home but can also be provided in a nursing home, assisted living facility or hospital. Key services provided include pain and symptom management accompanied by palliative medication, emotional and spiritual support, spiritual counseling and family bereavement counseling, inpatient and respite care, homemaker services, dietary counseling and social worker visits for up to 13 months after a patient’s death.

Facility-Based Services

The Company’s LTACHs treat patients with severe medical conditions who require a care and frequent monitoring by physicians and other clinical personnel. Patients who receive its services in an LTACH are too medically unstable to be treated in a non-acute setting. It also treats patients diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living. As part of its facility-based services, the Company operates an institutional pharmacy, which focuses on pr oviding a full array of services to its long-term acute care hospitals. All coding, medical records, case management, utilization review and medical staff credentialing are provided at the hospital level. Centralized functions that are provided by the home office include payroll, accounting, financial reporting, billing, collections, regulatory and legal compliance, risk management, pharmacy, information technology and general clinical oversight accomplished by periodic on-site surveys.

Advisors’ Opinion:

  • [By Sean Williams]

    What: Shares of home health providers Amedisys (NASDAQ: AMED  ) , Gentiva Health Services (NASDAQ: GTIV  ) , and LHC Group (NASDAQ: LHCG  )  swooned as much as 28%, 20%, and 15%, respectively, following a public proposal by the Centers for Medicare and Medicaid Services, or CMS, late yesterday that in-home health care reimbursements be cut by 1.5% in 2014.

Top High Tech Companies To Buy For 2015: Vertex Pharmaceuticals Incorporated(VRTX)

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Ben Levisohn]

    The Fed minutes suggested a dovish course for monetary policy, helping to boost stocks as Visa (V), Boeing (BA), Facebook (FB), Vertex Pharmaceuticals (VRTX) and International Business Machines (IBM) rose.

  • [By Ben Levisohn]

    It’s hard not to think it might be. Today, Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Celgene (CELG), Amgen (AMGN) and Vertex Pharmaceuticals (VRTX).

  • [By Ben Levisohn]

    Stocks bucked their recent Monday weakness today as Visa (V), International Business Machines (IBM), United Technologies (UTX), Micron Technology (MU) and Vertex Pharmaceuticals (VRTX) gained. But your view of today likely depended on the index you were watching.

  • [By Jon C. Ogg]

    A larger concern is this “lost in translation” issue. This REIT is acquiring 2 biomedical office buildings that are 96% occupied, with a 15-year term with Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Vertex is now worth almost $20 billion and is expected to be profitable in 2015. Senior Housing will almost certainly get an earnings boost from this lease, but there is one small problem here – most investors believe that they are investing in a company that makes its bread and butter from senior living facilities. Owning biotech leases of healthy large companies is not a bad business; it just changes the focus of the company because this will add about 20% or so in size.

Top High Tech Companies To Buy For 2015: Global Indemnity plc (GBLI)

Global Indemnity plc, through its subsidiaries, operates as a specialty property and casualty insurer. The company provides property and casualty insurance products in the excess and surplus lines marketplace to customers in the United States, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. It offers property and general liability products for small commercial businesses through a network of wholesale general agents; property, general liability, and professional lines products through program administrators; and property, casualty, and professional lines products through wholesale brokers. The company also provides reinsurance solutions to excess and surplus lines carriers, specialty property and casualty insurance companies, and regional insurance writers. It offers reinsurance solutions worldwide through brokers; primary writers, including regional insurance companies; and program managers. Global Indemnity plc is based in Dublin, Ireland.

Advisors’ Opinion:

  • [By Damian Illia]

    As we can see, the firm ratio is higher than the ones shown by Alleghany, Fidelity, Federated National Holding Co. (FNHC) and Global Indemnity Plc (GBLI).

Top High Tech Companies To Buy For 2015: Capstead Mortgage Corporation (CMO)

Capstead Mortgage Corporation operates as a self-managed real estate investment trust. It invests in leveraged portfolio of residential mortgage pass-through securities consisting of adjustable-rate mortgage securities issued and guaranteed by government-sponsored enterprises or by an agency of the federal government. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1985 and is headquartered in Dallas, Texas.

Advisors’ Opinion:

  • [By Bryan Perry]

    Yes and no. I don’t like the risk/reward for fixed-rate mREITs. I’m concerned we could see a spike in the 10-year Treasury note to 3.5% if the economy picks up speed, which will put fixed-rate mREITs under pressure. That said, I think there are select adjustable-rate mREITs that are worthy of a spot in your portfolio. One I do recommend in my Cash Machine Aggressive High-Yield portfolio is Capstead Mortgage (CMO).

  • [By Amanda Alix]

    In a show of bravado, several mREITs have declared dividends within the past week, with nary a decrease in sight. Capstead Mortgage (NYSE: CMO  ) just announced the continuation of its $0.31 per share quarterly dividend, which was upped from $0.30 just this past March. CYS Investments (NYSE: CYS  ) revealed its intention to raise its own quarterly payout to $0.34 from $0.32 per share earlier this week, and Armour Residential (NYSE: ARR  ) has joined in, keeping its monthly $0.07 per share dividend firmly in place, even into the third quarter.

Top High Tech Companies To Buy For 2015: Becton Dickinson and Company(BDX)

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company?s BD Medical segment produces medical devices that are used in various healthcare settings. This segment?s products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes, pen needles, and other drugs to treat diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Diagnostics segment provides products for the safe collection and transport of diagnostics specimens, as well as instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment?s products consist of integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. The company?s BD Biosciences segment produces research and clinical tools that facilitate the study of cells and their components. This segment?s products comprise fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. It markets its products through independent distribution channels and independent sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Advisors’ Opinion:

  • [By Ingrid Hendershot]

    Becton Dickinson (BDX) yields 1.9% and has raised its dividend for 42 years.

    Brown-Forman (BF-B) yields 1.6% and has raised its dividend for 30 years.

  • [By Victor Selva]

    The company has a very attractive current ratio of 33.03% which is higher than its comps: Becton Dickinson & Co (BDX), Cardinal Health Inc (CAH), Cooper Companies (COO) and Luxottica Group S.p.A. (LUX).

  • [By Peter Stephens]

    The competition
    In terms of competition, medical devices and diagnostics accounted for 21% of Abbott Labs’  (NYSE: ABT  )  total sales in 2013, with Becton, Dickinson  (NYSE: BDX  )  also focusing on this area. Abbott experienced a strong year in this space and delivered total sales growth of 5.9%, even when a negative currency impact of 2.4% is taken into account. A 10.8% increase in volume drove the growth, while competitive pricing had a negative impact on total sales. However, reduced prices did not translate into falling margins, as Abbott drove through significant efficiencies so as to increase operating margin from 19.2% in 2011 to 22.2% in 2013, with a more focused and leaner supply chain making a big difference.

  • [By Rich Duprey]

    Medical device maker Becton, Dickinson  (NYSE: BDX  ) gave investors a shot in the arm today reporting strong financial results for its second fiscal quarter and raising its guidance for the full year.